Utah Governor’s Office of Economic Development

NeuroAdjuvants, Inc. will develop and commercialize a proprietary platform technology enabling multiple “firstinclass” neuropeptidebased
therapeutics for a wide variety of neurologic and psychiatric disorders. This platform provides a breakthrough ability to harness therapeutic potential of neuropeptides and provides both stability & bloodbrainbarrier permeability. The initial focus is to identify novel therapies for pain and epilepsy with future
potential applications to other neurologic and psychiatric disorders.

Theodore Stanley
417 Wakara Way, Suite 3111
Salt Lake City, UT  84108
(801) 585-6330
teds@neuroadjuvants.com